Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 13/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 10/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3783019 | 1.00 | MAPK9 (0.52) | MAPK9MAPK10MAPK8KDM4ESMN1; SMN2 | |
| SCHEMBL3780636 | 0.88 | KDM4E (0.48) | MAPK9MAPK10MAPK8KDM4EALDH1A1 | |
| SCHEMBL29456233 | 0.88 | KDM4E (0.48) | MAPK9MAPK10MAPK8KDM4EALDH1A1 | |
| SCHEMBL29456264 | 0.84 | MAPK9 (0.53) | MAPK9MAPK10MAPK8 | |
| SCHEMBL3720591 | 0.84 | MAPK9 (0.53) | MAPK9MAPK10MAPK8 | |
| SCHEMBL29456267 | 0.83 | MAPK9 (0.52) | MAPK9MAPK10MAPK8 | |
| SCHEMBL3782016 | 0.83 | MAPK9 (0.52) | MAPK9MAPK10MAPK8 | |
| SCHEMBL3720936 | 0.82 | MAPK8 (0.50) | MAPK9MAPK10MAPK8KDM4ESMN1; SMN2 | |
| SCHEMBL29456313 | 0.82 | MAPK8 (0.50) | MAPK9MAPK10MAPK8KDM4ESMN1; SMN2 | |
| SCHEMBL14564395 | 0.81 | MAPT (0.51) | KDM4ESMN1; SMN2ALDH1A1HSD17B10CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.